Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know.

Virani SS, Koschinsky ML, Maher L, Mehta A, Orringer CE, Santos RD, Shapiro MD, Saseen JJ. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Progress in Cardiovascular Diseases. 2022 Jul 1; 73:32-40.

Related HSR&D Project(s)

• IIR 16-072 – Determining and targeting reasons for low statin use to improve guideline-concordant statin therapy in high-risk patients

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

Evidence from Mendelian randomization studies suggest that lipoprotein(a) (Lp(a)) has a causal role in the development of atherosclerotic cardiovascular disease risk. However, guidelines and consensus statement recommendations vary regarding how clinicians should incorporate Lp(a) into patient care. To provide practical answers to key questions pertaining to Lp(a) that clinicians will find useful when assessing and treating patients, a global think tank was convened. Representatives from seven national and international stakeholder organizations answered questions that were focused on: Lp(a) measurement; ethnic, gender, and age considerations; factoring Lp(a) into risk assessment; and current and emerging treatment options for elevated Lp(a). This manuscript summarizes the finding from this global think tank. Areas requiring further investigation were identified, and the need to standardize reporting of Lp(a) levels to ensure harmonization and comparability across laboratories and research studies is emphasized.